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Abstract
Background: Early diagnosis of pancreatic carcinoma with highly sensitive diagnostic imaging methods could save lives of
many thousands of patients, because early detection increases resectability and survival rates. Current non-invasive
diagnostic imaging techniques have inadequate resolution and sensitivity for detection of small size (,2–3 mm) early
pancreatic carcinoma lesions. Therefore, we have assessed the efficacy of positron emission tomography and computer
tomography (PET/CT) imaging with b-O-D-galactopyranosyl-(1,49)-29-deoxy-29-[
18F]fluoroethyl-D-glucopyranose ([
18F]FEDL)
for detection of less than 3 mm orthotopic xenografts of L3.6pl pancreatic carcinomas in mice. [
18F]FEDL is a novel
radioligand of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein (HIP/PAP), which is overexpressed in
peritumoral pancreatic acinar cells.
Methodology/Principal Findings: Dynamic PET/CT imaging demonstrated rapid accumulation of [
18F]FEDL in peritumoral
pancreatic tissue (4.0462.06%ID/g), bi-exponential blood clearance with half-lives of 1.6560.50 min and 14.1463.60 min,
and rapid elimination from other organs and tissues, predominantly by renal clearance. Using model-independent graphical
analysis of dynamic PET data, the average distribution volume ratio (DVR) for [
18F]FEDL in peritumoral pancreatic tissue was
estimated as 3.5760.60 and 0.9460.72 in sham-operated control pancreas. Comparative analysis of quantitative
autoradiographic images and densitometry of immunohistochemically stained and co-registered adjacent tissue sections
demonstrated a strong linear correlation between the magnitude of [
18F]FEDL binding and HIP/PAP expression in
corresponding regions (r=0.88). The in situ analysis demonstrated that at least a 2–4 fold apparent lesion size amplification
was achieved for submillimeter tumors and to nearly half a murine pancreas for tumors larger than 3 mm.
Conclusion/Significance: We have demonstrated the feasibility of detection of early pancreatic tumors by non-invasive
imaging with [
18F]FEDL PET/CT of tumor biomarker HIP/PAP over-expressed in peritumoral pancreatic tissue. Non-invasive
non-invasive detection of early pancreatic carcinomas with [
18F]FEDL PET/CT imaging should aid the guidance of biopsies
and additional imaging procedures, facilitate the resectability and improve the overall prognosis.
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Introduction
The estimated number of new cases of pancreatic cancer in the
United States in 2009 is 42,470 and the estimated number of
deaths is 35,240 [1]. Although, pancreatic cancer accounts for
only 2% of all malignancies, it is the fourth most common cause of
cancer death in the United States. Such a poor prognosis for
patients with pancreatic cancer is because 80–90% of patients
have unresectable disease at the time of diagnosis [2]. It is widely
accepted that the overall and disease-free survival of patients with
pancreatic carcinoma are related to the possibility of complete
macroscopic R0 resection [3]. Prognosis is also related to tumor
size (,30 mm), nodal involvement and resection margin status [4].
Therefore, early diagnosis of pancreatic carcinoma with highly
sensitive diagnostic imaging methods is very important and could
save lives of many thousands of patients, because early detection of
small pancreatic cancers is likely to increase resectability rates.
Due to inadequate resolution and sensitivity of
18F-FDG PET/
CT imaging (,5 mm in plane) for detection of small size (,2–
3 mm) early pancreatic carcinoma lesions [5], we have focused on
the development of imaging agents for visualization of tumor-
induced biomarkers that are over-expressed in the peritumoral
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7977pancreratic tissue. Such an approach should generate the ‘‘lesion
size amplification’’ effect and result in at least 3 to 4 fold increase
in the apparent lesion size. Such an approach could potentially
improve the overall detectability of pancreatic tumor lesions at
early stages of their development, improve their respectability, and
the overall prognosis.
Among pancreatic tumor biomarkers produced in peritumoral
reactive pancreatic tissue, the hepatocarcinoma-intestine-pancreas/
pancreatitis-associated protein (HIP/PAP) was found to be over-
expressed more than 130-fold in pancreatic acinar cells, as
compared to normal pancreas [6]. In contrast, only a 9-fold
increased expression of HIP/PAP protein was observed in acinar
cells in chronic pancreatitis. Also, fragments of HIP/PAP protein
are immunodetectable in blood and their levels correlate with the
severity of pancreatic inflammation and pancreatic carcinoma size
[7]. Furthermore, HIP/PAP protein is a promising target for the
development of imaging agents, because it is also overexpressed in
hepatocellular and cholangial carcinomas withinthetumor cells[8].
The HIP/PAP proteinis a 16 kDsecreted protein,whichbelongs
to the group VII of a family of proteins that contain a C-type lectin
like domain, according to Drickamer’s classification [9], which
binds carbohydrates, and that it is also known as the ‘‘lactose-
binding protein’’ (for review [10]. Previous biochemical studies
demonstrated that GST-purified recombinant HIP/PAP protein
has a very high affinity to D-lactose, but insignificantly to a-D-
glucopyroanose, a-L-fucose, a-D-galactopyranose, or N-acetyl-b-
D-glucosamine [11]. We hypothesized, that the HIP/PAP (the
lactose-bindingprotein)shouldbindminimallymodified
18F-labeled
lactose analogues with high affinity, and that this ‘‘receptor-ligand’’
type of an imaging approach should allow for visualization of
peritumoral infiltrated pancreatictissue that 130-fold over-expresses
the HIP/PAP protein, as compared to normal pancreatic tissue.
Furthermore,ourenthusiasmwassupportedbya previousreporton
biodistribution of b-O-D-galactopyranosyl-(1,49)-29-[
18F]fluoro-29-
deoxy-D-glucopyranose ([
18F]FDL) in mice, which demonstrated
that [
18F]FDL was not accumulating in any of the major organs and
was rapidly cleared from the circulation by renal clearance and
appeared in urine as non-metabolized parent compound, [
18F]FDL
[12]. Recently, we reported on the optimized radiosynthesis of b-O-
D-galactopyranosyl-(1,49)-29-deoxy-29-[
18F]fluoroethyl-D-glucopy-
ranose ([
18F]FEDL) [13].
In this paper we demonstrate the efficacy of microPET/CT
with [
18F]-FEDL for detection of early microscopic pancreatic
carcinoma lesions in a bioluminescent variant of an orthotopic
pancreatic carcinoma xenograft model in mice. The results of non-
invasive in vivo PET/CT imaging were validated by comparative in
situ autoradiographic and immunohistochemical analyses. We
conclude, that non-invasive detection of early pancreatic carcino-
mas with [
18F]FEDL PET/CT imaging should aid the guidance of
biopsies and additional imaging procedures, facilitate the resect-
ability and improve the overall prognosis.
Results
Orthotopic Pancreatic Tumor Xenograft Model
In the Group I mice (N=12), non-invasive bioluminescence
imaging (BLI) was used for monitoring the growth of orthotopic
pancreatic carcinoma xenografts. Distinct bioluminescence imaging
(BLI) signal was detectable in the area consistent with the site of the
L3.6pl/GL+ cell injection already on day 4 (Fig. 1A) and increased
exponentially by day 10 post injection (Fig. 1A,B). Based on the
results of BLI, PET/CT imaging studies in Group I, subsequent
PET/CT imaging studies with [
18F]FEDL were performed 7 days
after injection of L3.6pl/GL+ cells, when the tumor diameter was
1.860.9 mm. However, based on the IHC analysis of pancreatic
tissue sections, the apparent diameter of the lesion based on the
expression of HIP/PAP in peritumoral pancreatic tissue ranged
from 2 mm for sub-millimeter sized tumors (Fig. 1C) to almost a
half of the pancreas (10–12 mm) for tumors of 2–3 mm in diameter.
In all cases, at least a 2–4 fold amplification of the apparent tumor
lesion size was observed, based on the extent of HIP/PAP
expression in the peritumoral pancreas.
PET/CT with [
18F]FEDL
Dynamic PET imaging demonstrated a rapid accumulation of
[
18F]FEDL in the area of L3.6pl/GL+ tumor growth with
characteristically concentric or a horseshoe pattern (Fig. 2A–C),
which corresponds to the pancreatic tail adjacent to the visceral
surface of the spleen and anterior to the upper pole of the left
kidney. Model-independent graphical analysis of dynamic PET
imaging data (Logan plot) using muscle as the reference tissue
devoid of HIP/PAP protein expression, the average distribution
volume ratio (DVR) for [
18F]FEDL in peritumoral pancreatic
tissue was 3.5760.60 and with the binding potential (BP) of
2.5760.60 (Fig. 2F). In sham-operated control animals, the DVR
for [
18F]FEDL in the pancreas was 0.9460.72. The differences in
DVR and BP between tumor-bearing and sham-operated control
animals were statistically significant (p,0.01).
There was no specific retention of the [
18F]FEDL-derived
radioactivity observed in other organs and tissues, except for kidneys,
ureters and urinary bladder, which involved in normal physiologic
clearance of this radiotracer. Clearance of [
18F]FEDL-derived
radioactivity from major organs and tissues followed the kinetics of
blood clearance (Fig. 2D,E). Clearance of [
18F]FEDL from the
circulation exhibited a bi-exponential kinetics with half-lives of
1.6560.50 min and 14.1463.60 min, respectively (Fig. 2D). At
60 min post i.v. injection, the level of [
18F]FEDL in blood was
0.5160.24%ID/ml, determined from the maximum pixel activity
within the ROI placed over the heart region. No accumulation of
[
18F]FEDL-derived radioactivity was detected in the skeletal
structures up to 60 min post injection of [
18F]FEDL. The
biodistribution of [
18F]FEDL-derived radioactivity indifferent organs
and tissues at 60 min post i.v. injection is provided in Table 1.
In Vivo [
18F]FEDL Autoradiography and HIP/PAP
Expression
In situ validation of in vivo [
18F]FEDL PET/CT imaging was
performed at the end of each dynamic imaging study using
comparative analysis with autoradiography and immunohisto-
chemistry of HIP/PAP expression in the pancreas. Distribution of
[
18F]FEDL-derived radioactivity in a block of tissues (Fig. 3A),
including pancreas, spleen and a segment of intestine demonstrat-
ed high levels of [
18F]FEDL binding accumulation in the
peritumoral reactive pancreatic tissue (blue rectangle Fig. 3B,
shown magnified in 3D), which was consistent with the high level
of HIP/PAP expression observed in peritumoral pancreatic tissue
in the corresponding area (Fig. 3C). Comparative densitometric
analysis of autoradiographic and IHC images demonstrated a
good linear correlation (r=0.88) between the magnitude of in vivo
accumulation of [
18F]FEDL and the level of HIP/PAP protein
expression in different regions of peritumoral pancreas (Fig. 3E).
Ex Vivo [
18F]FEDL Autoradiography and HIP/PAP
Expression
Additional evaluation of radioligand properties of [
18F]FEDL was
performed using comparative analysis of ex vivo autoradiography and
HIP/PAP immunohistochemistry (IHC) (Fig. 4). This experiment
PET/CT of Pancreatic Tumors
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mice bearing small orthotopic xenografts of L3.6pl/GL+ tumors
(Fig. 4A). The autoradiographic images demonstrated a peritumoral
pattern of [
18F]FEDL binding to the reactive pancreatic tissue (blue
rectangle Fig. 4B, shown magnified in 4E), which was consistent
with the high level of HIP/PAP expression observed in peritumoral
pancreatic tissue in the corresponding area (Fig.4H). In contrast, the
magnitude of [
18F]FEDL binding pancreatic tissue was significantly
lower in the regions remote from the site of tumor growth (red
rectangle Fig. 4B, shown magnified in 4D), which was consistent
with low (background levels of HIP/PAP expression in these remote
regions of pancreas (Fig. 4G). Pre-treatment of an adjacent tissue
section with1 mMlactose resulted in acomplete inhibitionofspecific
binding of [
18F]FEDL to pancreatic tissue (Fig. 4C). However, some
non-specific binding was still observed, which had punctuate or small
circular pattern the origins of which is, presumably, the intimal layer
of larger vessels and intestinal content (blue rectangle Fig. 4C,
magnified in 4F). Comparative densitometric analysis of autoradio-
graphic and IHC images demonstrated a good linear correlation
(r=0.88) between the magnitude of [
18F]FEDL binding and the level
of HIP/PAP protein expression in different regions (Fig. 4I).
Discussion
In the current study, we have demonstrated that the detection of
early stage pancreatic carcinomas is feasible using PET/CT with
[
18F]FEDL, a radioligand for HIP/PAP, which is selectively over-
expressed in peritumoral pancreatic acinar cells. The extent of
HIP/PAP over-expression in peritumoral pancreas resulted in a
significant amplification of the apparent lesion size: at least a 2–4
fold amplification of the apparent tumor lesion size for sub-
millimeter sized tumors to almost a half of the pancreas (10–
12 mm) for tumors of 2–2.5 mm in diameter. The magnitude of
peritumoral accumulation of [
18F]FEDL was proportional to the
level of HIP/PAP expression (r=0.88), as demonstrated by a
comparative densitometric analysis of QAR and IHC-stained
tissues sections. It is noteworthy, that such relationship with HIP/
PAP expression was observed using QAR after in vivo intravenous
administration of [
18F]FEDL (after PET/CT imaging) as well as
using ex vivo QAR (after incubation of frozen tissue section in
solution with [
18F]FEDL). The specificity of [
18F]FEDL binding
was confirmed by pre-blocking of the tissue sections with excess of
non-radiolabeled lactose. Together, these results further confirm
the specificity of [
18F]FEDL binding to the HIP/PAP protein-
expressing peritumoral pancreatic tissue.
To quantify the magnitude of [
18F]FEDL binding to peritu-
moral pancreatic tissue, we elected to utilize model-independent
Logan graphical analysis, due to the limitations of repetitive blood
sampling in mice, which hampers the radiolabeled metabolite
analysis from small volumes of plasma. Instead of the arterial
blood input function, the Logan graphical analysis utilizes time-
activity data from a reference tissue [14]. Ideally, normal
Figure 1. An orthotopic pancreatic tumor xenograft model in mice. (A) Bioluminescence images of mice with orthotopic tumors obtained at
4, 7, and 10 days post intra-pancreatic injection of L3.6pl/GL+ human pancreatic carcinoma cells. (B) Growth dynamics of the orthotopic L3.6pl/GL+
tumors based on the photon flux measured from BLI images obtained from the left mid-abdominal area. (C) HIP/PAP expression in peritumoral
pancreatic acinar cells and microvesels (620; bar=500 mm); the black dotted line defines the area shown at higher magnification (640) in panel (D).
doi:10.1371/journal.pone.0007977.g001
PET/CT of Pancreatic Tumors
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the reference tissue for peritumoral pancreatic tissue. However,
the results of our studies using in situ QAR and IHC demonstrated
in some cases a fairly extensive over-expression of HIP/PAP in
peritumoral pancreas. Therefore, we concluded that the use of
apparently normal pancreatic regions (not significantly accumu-
lating [
18F]FEDL) would be unreliable. In contrast, muscle tissue
does not express HIP/PAP and was used as a reference tissue for
the Logan graphical analysis. The calculated binding potential of
[
18F]FEDL in peritumoral pancreatic tissue using muscle as the
reference tissue was 2.5760.60, which was 20-fold higher than in
the pancreas of sham-operated control animals.
No significant accumulation of [
18F]FEDL-derived radioactivity
was detected in the skeletal structures up to 60 min post injection
of [
18F]FEDL, which suggests that the radiotracer was not
catabolized or de-fluorinated in vivo. The rapid whole body re-
distribution and fast renal clearance of [
18F]FEDL from
circulation make this radiotracer especially suitable for imaging
of the abdominal area, specifically of the pancreas and liver. A
similar pattern of radioactivity biodistribution was previously
reported for [
18F]FDL in normal NMRI mice and in transgenic
mice expressing b–galactosidase under the control of a ubiquitous
ROSA-26 promoter [12]. The similarity in biodistribution of
[
18F]FEDL and [
18F]FDL is not surprising, because the only
difference between these radiotracers is that in the [
18F]FDL, the
29-position of glucopyranose moiety is directly labeled with
18F-
fluoro group, while in the [
18F]FEDL, the same 29-position is
derivatized with a
18F-fluoroethyl side chain. The low level of
[
18F]FEDL-derived radioactivity in the pancreas, spleen, liver and
intestines at 60 min post i.v. injection may also enable the
detection of hepatocellular carcinomas and cholangial carcinoma
as well, because the HIP/HAP in known to be over-expressed by
the tumor cells (but not the peritumoral liver) [15,16].
Early detection of small pancreatic tumors will require screening
of asymptomatic subjects for pancreatic cancer. Despite the
demonstration of feasibility of [
18F]FEDL PET imaging as a
biomarker for detection of early pancreatic carcinomas in an
experimental animal model, this diagnostic imaging approach
alone can’t be justified for pancreatic tumor screening. This
diagnostic imaging approach, however, could be developed as a
Table 1. Radioactivity concentration (%ID/g) in different
organs and tissues measured by PET/CT at 60 min post
intravenous administration of [
18F]FEDL.
Tissue Average St.Err.
Blood 0.51 0.11
Brain 0.18 0.05
Muscle 0.21 0.03
Kidney 5.14 2.47
Liver 0.66 0.23
Lung 0.77 0.59
Spleen 0.22 0.08
Stomach 0.20 0.12
Intestine 0.17 0.11
Pancreas 0.38 0.22
Peritumoral pancreas 4.04 2.06
doi:10.1371/journal.pone.0007977.t001
Figure 2. In vivo dynamic PET/CT imaging with [
18F]FEDL. (A) Coronal, (B) axial, and (C) sagittal PET/CT images obtained at 60 min after i.v.
administration of [
18F]FEDL in a representative animal. (D) and (E) – time-activity curves of [
18F]FEDL-derived radioactivity concentration in
peritumoral pancreas and in different organs and tissues; points show means, bars – standard deviations. (F) Logan plot analysis to quantify the
distribution volume ratio (DVR) of [
18F]FEDL in peritumoral pancreas using muscle as a reference tissue for the representative animal shown in panels
A–C.
doi:10.1371/journal.pone.0007977.g002
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readily available bodily fluids and tissues, such as blood, pancreatic
juice obtained during endoscopic studies. Several genetic syn-
dromes such as familial pancreatitis, Peutz-Jeghers syndrome, and
familial atypical multiple mole melanoma are associated with an
increased risk of pancreatic cancer, in addition to mutations in the
tumor suppressor gene BRCA2 and several DNA mismatch repair
genes [17–21]. Currently, genetic syndromes with a high incidence
of pancreatic cancer are being targeted for screening [22,23] using
blood proteomic profiling [24], serum biomarkers, such as amyloid
A [25], RCAS1 [26], CA 19-9, etc. Translational studies are
underway to discover novel molecular biomarkers such as up-
regulated genes and over-expressed proteins specific for pancreatic
carcinomas that could be detected in serum and pancreatic juice.
Among the DNA based biomarkers, K-ras mutations are present
in 90% of pancreatic cancer. Therefore, other groups have been
developing novel PET imaging agents targeting KRAS oncogene,
such as the [
64Cu]DO3A-PNA-peptide [27]. Both mRNA and
protein levels of telomerase reverse transcriptase (hTERT) are
significantly elevated in pancreatic juice of almost 90% of patients
with pancreatic carcinomas [28,29]. Several other proteins or
protein fragments are up-regulated in pancreatic carcinoma cells
and can be identified in blood (serum) using two dimensional gel
electrophoresis or mass spectrometry or antibody-based methods.
Recently, it was demonstrated that MUC1 is upregulated in blood
of more than 90% of patients with pancreatic carcinoma [30]. The
Figure 3. Autoradiography of [
18F]FEDL distribution after intravenous administration and HIP/PAP expression. (A) H&E stained
section and (B) color-coded autoradiographic image of [
18F]FEDL-derived radioactivity distribution in an adjacent section obtained from the same
tissue block including: pancreas, spleen and intestine and a small orthotopic pancreatic carcinoma lesion outlined by the dotted lines (bar: 5 mm)
and indicated by the arrows; a blue dotted line outlines the area shown at 615 higher magnification in panel (C) IHC of HIP/PAP and (D)
autoradiography of [
18F]FEDL-derived radioactivity distribution. High level of [
18F]FEDL radioactivity is seen in the peritumoral pancreatic tissue, but
not in the tumor lesion. (E) A scatter plot and linear regression analysis of relationship between the magnitude of HIP/PAP expression (IHC
densitometry, ROD) and [
18F]FEDL accumulation in peritumoral pancreatic tissue (autoradiography, PSL/mm
2); an almost linear relationship is
observed (r=0.88).
doi:10.1371/journal.pone.0007977.g003
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precursor lesions, but is not detected in normal pancreas. The
overall sensitivity and specificity of ELISA for MUC-1 in serum
were 82% and 85%, respectively, which is consistent with previous
results. An exciting finding in their study is that 92% of stage I
cancer cases were above cutoff value for positive response. A
positive correlation was observed for mean concentration of
MUC-1 in the serum with stage of disease. The same group has
recently developed a bivalent
111In-DOTA-labeled antibody to
MUC-1 and reported on successful gamma scintigraphy results in
mice bearing s.c. xenografts of pancreatic carcinoma [31]. In the
latter study, superior imaging results were obtained using the non-
radiolabeled bivalent antibody for pretargeting of a radiolabeled
TF-10 hapten peptide.
Serum levels of circulating HIP/PAP are also significantly
elevated in pancreatic cancer the level of HIP/PAP correlates with
tumor load, nodal involvement, distant metastasis and short
survival [32,33]. HIP/PAP protein was also elevated in pancreatic
juice in patients with both pancreatic carcinoma and to the lesser
magnitude in chronic pancreatitis and could be used to detect
early pancreatic injury [34]. Therefore we suggest that ELISA
measurements of serum HIP/HAP and MUC-1 levels could be
added to a panel of tests for the routine screening of population to
identify individuals at increased risk for the developing pancreatic
carcinoma. Then, in HIP/HAP-positive individuals [
18F]FEDL
PET/CT imaging could be performed to identify the location of
potential pancreatic carcinoma. Te [
18F]FEDL PET/CT could
then be followed by more invasive diagnostic imaging approaches,
such as endoscopic sonography and endoscopic retrograde
cholangio-pancreatography (ERCP), which have been successfully
used to detect precancerous lesions in an autosomal dominant
familial pancreatic cancer with high penetrance [22].
Figure 4. Comparison of ex vivo [
18F]FEDL autoradiography and HIP/PAP expression. (A) H&E stained section and (B) color-coded
autoradiographic image of [
18F]FEDL binding in an adjacent section obtained from the same tissue block including: pancreas, spleen and intestine
and two small orthotopic pancreatic carcinoma lesions outlined by the dotted lines (bar: 5 mm) and indicated by the arrows; a red dotted line
outlines the area shown at 615 higher magnification in panel D (autoradiography) and panel G (IHC) with low level of HIP/PAP expression; a blue
dotted line outlines the area shown in panel E (autoradiography) and H (IHC) with high level of HIP/PAP expression. (C) autoradiographic image of an
adjacent section blocked with 1mM lactose prior to exposure to [
18F]FEDL. A non-specific binding is observed to the intestinal content and to the
vascular- or ductal-appearing structures in the pancreras and spleen. (F) 615 magnified autoradiographic image of the region outlined by the blue
dotted rectangle in panel C, demonstrating some non-specific binding of [
18F]FEDL. (I) A scatter plot and linear regression analysis of relationship
between the magnitude of HIP/PAP expression (IHC densitometry, ROD) and [
18F]FEDL binding (autoradiography, PSL/mm
2); an almost linear
relationship is observed (r=0.88).
doi:10.1371/journal.pone.0007977.g004
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carcinomas could be detected with PET/CT with [
18F]FEDL, a
radioligand for HIP/PAP, which is selectively over-expressed in
peritumoral pancreatic acinar cells. Molecular imaging of tumor-
specific biomarkers, such as HIP/PAP, over-expressed in peritu-
moral reactive pancreatic tissue generates the ‘‘lesion size
amplification’’ effect and improves the detectability of small
pancreatic tumors that are otherwise poorly detectable by
conventional non-invasive imaging modalities. When translated
into the clinic, [
18F]FEDL PET/CT imaging should enable earlier
diagnosis of pancreatic carcinomas, guide additional diagnostic
procedures, facilitate earlier surgeries and thus improve patients’
survival.
Materials and Methods
Cell Culture and Gene Transduction
Human pancreatic cancer cells L3.6pl were kindly provided by
Prof. Isaiah J. Fidler (UT-MD Anderson, Houston, TX). The
L3.6pl cells were stably transduced with a retroviral vector bearing
a dual reporter gene, termed GL, which is a tandem fusion of the
green fluorescence protein and firefly luciferase genes. Transduced
L3.6pl/GL+ cells were selected by FACS and characterized for
fluorescence and bioluminescence properties as previously de-
scribed [35]. The L3.6pl/GL+ cells were grown in flasks with
DMEM/F12, supplemented with 10% fetal bovine serum,
penicillin and streptomycin, at 37uC in a humidified atmosphere
with 5% CO2. The cells were harvested by trypsinization; after
centrifugation of cell suspension at 5000 rpm for 5 min the culture
medium was aspirated, and the cell pellet was re-suspended in
10% heat inactivated serum obtained from nu/nu athymic nude
mice (Charles River, Wilmington, MA) for ortothopic injection, as
described below.
Orthotopic Pancreatic Tumor Model
All studies in animals were performed according to protocol
approved by the Institutional Animal Care and Use Committee of
the UT MD Anderson Cancer Center. Four to six weeks old
athymic nude mice (N=8, nu/nu, Charles River, Wilmington,
MA) were anesthetized by isoflurane inhalation (2–2.5% in
oxygen). A small incision (2 cm) was made in the left abdominal
wall. The spleen was then exteriorized along with the underlying
pancreas and approximately 1610
7 of L3.6pl-GL+ cells suspended
in mouse serum were slowly injected directly into the tail of the
pancreas, as previously described [36]. Sham operated control
group of animals (N=8) received no injections into the pancreas to
avoid non-specific inflammatory response, which could induce
HIP/PAP expression in the pancreas around the site of injection.
Then, the wound was closed with nylon sutures and treated with
antibacterial, antimycotic cream. After the operation, the animals
were warmed and monitored until conscious and then placed in
HEPA-filtered cages with feed and water ad libitum.
Bioluminescence Imaging
To monitor tumor development, the mice were given a single
150-mg/kg intraperitoneal dose of the D-luciferin (Xeno-
gen,CA) on days 4, 7, and 10 after tumor implantation. Under
the gas anesthesia (2% isoflurane in oxygen), the animals were
placed into the light-tight chamber of the IVIS200 imaging
system (Xenogen Corp., Almeda, CA). Bioluminescence images
were acquired using the following parameters: image acquisition
time 1–5 sec; binning 2; no filter; f/stop; field view, 10 cm. The
signal intensity was quantified as sum of all detected photons
within the region of interest per second per cm
2 per steradian
(ph/s/cm
2/sr), using Living Image software (Xenogen Corp.,
Almeda, CA).
Radiosynthesis of [
18F]-FEDL
Detailed radiosynthesis procedure for [
18F]-FEDL has been
reported by us elsewhere [13]. Briefly, initial radiofluorination
reactions were carried out using b-O-D-galactopyranosyl-2,3,4,6-O-
tetraacetyl-(1–49)-[29-trifluoromethanesufonyl-39,69,-O-dibenzoyl-19-O-eth-
yl]-D-mannopyranose precursor and Bu4N[
18F]F in anhydrous
acetonitrile at 80uC for 20 min to produce [
18F]-FEDL. The
crude product was passed through a silicagel SepPak cartridge and
eluted with ethyl acetate. Then, the radiolabeled crude interme-
diate was purified using preparative HPLC. Then, the solvent was
evaporated in vacuo and the radiolabeled intermediate was
hydrolyzed with 0.5 M NaOMe in methanol at 80uC for 5 min.
The final product was neutralized with 1N HCl. The purity of the
[
18F]-FEDL product was verified by TLC and HPLC.
PET/CT Imaging
PET/CT imaging was performed using small animal PET/CT
scanner INVEON (Siemens Preclinical Solutions, Knoxville,
TN). Pancreatic tumor bearing mice (N=8) were anesthetized
with isoflurane (2% in oxygen) and their temperature kept at
38uC with a heat lamp. The CT imaging parameters were X-ray
voltage of 80kVp, anode current of 500 mA, an exposure time of
300–350 milliseconds of each of the 360 rotational step.
Dynamic PET imaging studies were acquired during 0–
60 minutes after administration of [
18F]-FEDL (3,7 MBq, in
100 mL of saline) intravenously asas l o wb o l u so v e r 1m i nw h i l e
the animals were positioned inside the gantry of the scanner.
Images were reconstructed using two dimensional ordered
subsets expectation maximization (OSEM) algorithm. PET and
CT image fusion and image analysis were performed using
software ASIPro 5.2.4.0 (Siemens Preclinical Solutions, Knox-
ville, TN).
Image Analysis and Quantification of Receptor Binding
Potential
Regional radioactivity concentrations (KBq/cm
3 or mCi/cm
3)
were estimated from the maximum pixel intensities within regions
of interest (ROIs) drawn around the tumor or organ on trans-axial
slices of the reconstructed image sets. The radioactivity uptake in
the peritumoral area of pancreas, in the heart and muscle were
converted to percent of injected dose per gram of tissue (%ID/g).
Logan graphical analysis [14] of the dynamic ROI data was used
to assess the magnitude of [
18F]-FEDL accumulation in the
peritumoral pancreas. The ratio of integrated radioactivity
concentration in peritumoral pancreas divided by the radioactivity
concentration at given time point tumor uptake was set as the y-
axis. The ratio of integrated reference tissue uptake divided tumor
uptake was set s the x-axis of a Logan plot. The muscle as
reference tissue because it has now HIP/PAP expression, while the
possibility of HIP/PAP expression in remote regions of ‘‘normal’’
pancreas could not be excluded a priori. The slope of the linear
portion of the Logan plot was distribution volume ratio (DVR). If
metabolite corrected plasma curves are not available, the plasma
curve can be replaced with reference region curve Cr(t). Then the
slope of the linear portion of the lot is DVR:
Ð t
0
Cmuscle t ðÞ dt
Cmuscle T ðÞ
~DVR
Ð t
0
Ctumor t ðÞ dt
Cmuscle T ðÞ
zC ð1Þ
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BP~DVR{1 ð2Þ
Quantitative Autoradiography (QAR)
After PET imaging, the animals were sacrificed and pancreas
with surrounding organs was rapidly extracted, frozen, and
embedded in a mounting medium M1 (Shandon-Lipshaw,
Pittsburg, PA). Serial 20 mm thick coronal sections of frozen
tissues at were obtained at 213uC using a cryomicrotome
(CM3050S, Leica, Germany). Tissue sections were thaw-mounted
on poly-A lysine coated glass slides and heat-fixed for 5 min at
65uC on a slide warmer (Fischer Scientific, PA). For QAR, tissue
sections were exposed to the phosphor plate (Fujifilm Life Science,
Woodbridge, CT) along with set of 20 mm autoradiographic
standards of known
18F radioactivity concentration, freshly
prepared using calf liver homogenate. Knowing the radioactivity
concentration in standards and the injected dose, the autoradio-
graphic images were converted to color-coded parametric images
of percent injected dose/g tissue (%ID/g) using MCID Elite image
analysis software version 7.0 (Imaging Research Inc., St.
Cathrines, Ontario, Canada).
For ex vivo QAR, 150 ml of saline containing [
18F]-FEDL
(240 mCi/15 ml) was gently applied directly onto glass slides
containing frozen pancreatic tumor tissue sections with peritu-
moral pancreas, obtained from a separate group of tumor
xenograft-bearing animals (not injected i.v. with the radiotracer).
The tissue sections were placed in a humidified black box to
reduce evaporation at room temperature for 60 min. The excess
radioactivity was washed thrice by consecutive dipping in ice-cold
PBS/Triton X-100 (0.01%) at pH 7.4. To assess the specificity of
[
18F]-FEDL binding, adjacent tissue sections were pre-blocked
with cold lactose (1 mmol) for 30 min and then incubated with
[
18F]-FEDL, as described above. Both sets of slides were dried and
exposed to phosphor plate (FLA5100, Fuji Photo Film Co., Tokyo
Japan) for 6–8 hrs.
Immunohistochemistry for HIP/PAP
The IHC for HIP/PAP was performed both in paraffin-fixed
tissue sections and in frozen tissue sections, as required. Frozen
sections (20 mm) or paraffin-embedded sections (5 mm thick) were
incubatedin3%aqueousH2O2 toblocktheendogenousperoxidase
activity, washed and then incubated in 2% normal horse blocking
serum for 60 minutes at room temperature. Thereafter, the sections
were incubated with monoclonal anti-mouse Reg II antibody (R&D
System Inc., Minneapolis, MN) at 1:50 dilution in Tris-NaCl
overnight at 4uC. Then, the sections were incubated with the
secondary biotinylated horse anti-mouse IgG, followed by avidin-
peroxidase conjugation and 393-diaminobenzidine chromophore
development steps using Vectastain ELITE kit (Vector Laborato-
ries, Burlingame, CA) according the manufacturer’s protocol. The
tissue sections were either counterstained with hematoxylin or used
without counterstaining for densitometric analysis of the intensity of
HIP/PAP immunostaining.
[
18F]-FEDL Binding Relative to HIP/PAP Expression
Using MCID Elite software version 7.0 (Imaging Research Inc.,
St. Cathrines, Ontario, Canada), the IHC-stained tissue sections
were digitized and co-registered with the corresponding adjacent
QAR images. The radioactivity concentration (%ID/g) in QAR
images was quantified in ROIs as described above. For ex vivo
autoradiography, the phosphor plate image intensity was quanti-
fied as units of photo-stimulated luminescence per square mm
(PSL/mm
2). The intensity of immunostaining for HIP/PAP in
corresponding ROIs in adjacent tissue sections was quantified by
densitometry and expressed as relative optical density (ROD). The
data was plotted against each other and linear regression analysis
performed to assess the relationship.
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